ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Files An 8-K Submission of Matters to a Vote of Security Holders


ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07.Submission of Matters to a Vote of Security Holders.

On December21, 2016, Actinium Pharmaceuticals, Inc. (Actinium)
held its 2016 Annual Meeting of Stockholders (the Annual
Meeting). Of the 55,747,108 shares of the Companys common stock
outstanding and eligible to vote at the Annual Meeting,
29,334,121 shares, or approximately 52.6% of the eligible common
stock, were present either in person or by proxy.All matters
submitted to a vote of the Companys stockholders at the Annual
Meeting were approved and the director nominee was elected. The
final results of the matters voted on at the Annual Meeting are
provided below.

Proposal 1: The following individual was elected as a
director to hold office for the term described below or until his
resignation, or respective successor is elected and qualified:

Director Name For Against Abstain Broker Non-Votes
Kaushik J. Dave (Class III, 36 month term) 9,472,599 3,156,465 376,893 16,062,482

Proposal 2: GBH CPAs, PC was ratified as the Companys
Independent Registered Public Accounting Firm for the fiscal year
ending December 31, 2017.

For: 26,835,760
Against: 1,808,733
Abstained: 423,946

Proposal 3: An amendment to the Companys 2013 Amended and
Restated Stock Plan to increase the number of shares authorized
to issue under the plan by 3.5 million shares was approved.

For: 8,082,170
Against: 4,233,093
Abstained: 690,694
Broker Non-Votes: 16,062,482

Proposal 4: A non-binding vote on 2015 executive
compensation was approved.

For: 8,772,044
Against: 3,943,740
Abstained: 340,173
Broker Non-Votes: 16,062,482


Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.


ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) closed its last trading session up +0.020 at 0.980 with 289,908 shares trading hands.